Effectiveness of Surgical and Diagnostic Methods in Cerebral Vascular Occlusive Disease (NCT07396025) | Clinical Trial Compass
By InvitationNot Applicable
Effectiveness of Surgical and Diagnostic Methods in Cerebral Vascular Occlusive Disease
Kazakhstan60 participantsStarted 2025-07-09
Plain-language summary
This study attempts to improve surgical treatment outcomes among people with chronic carotid artery occlusive disease by conducting a comprehensive review of neuroradiological, clinical, and cognitive data. The evaluation involves an extensive angiographic analysis, including pre- and postoperative measurements of superficial temporal artery branch diameters, assessment of the Circle of Willis and collateral pathways, alongside cerebral perfusion metrics, cognitive status, and clinical outcomes. Major focus is directed towards evaluating the degree of intracranial revascularization following to extracranial-intracranial bypass by postoperative angiographic evaluations. This integrative strategy aims to refine surgical reasons, better predictions of functional and cognitive outcomes, minimize postoperative risks, and eventually improve the overall efficacy of treatment in this patient population.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients with ICA occlusion confirmed by CTA, MRA, and cerebral DSA.
. MRI ASL-confirmed hypoperfusion in the territory of the occluded ICA (decrease of ≥30% compared with the contralateral side)
. Language comprehension is preserved, with mild or no motor aphasia and no significant cognitive impairment.
. Patients aged from 18 to 80 years.
. Modified Rankin Scale (mRS) score 0-2.
. Informed consent is available from the patient or legal guardian.
. Accessible and reliable patients for follow-up
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
STA-MCA bypass patency
Timeframe: From enrollment to the further follow-up of 6, 12, and 24 months.
2
Donor superficial temporal artery caliber
Timeframe: 6, 12, and 24 months after surgery
3
Cerebral perfusion changes
Timeframe: 6, 12, and 24 months after surgery
Trial details
NCT IDNCT07396025
SponsorNational Centre for Neurosurgery, Republic of Kazakhstan
. Patients with large territorial infarction or marked cerebral atrophy on MRI.
. No evidence of regional hypoperfusion on ASL MRI relative to the contralateral hemisphere.
. Patients with a non-functioning STA-MCA bypass
. Patients aged under 18
. Patients with severe somatic conditions or mRS score \> 3
. Patients with bilateral ICA occlusion, neurovascular disease (cerebral aneurysm or arteriovenous malformation)
. Patients with Contraindications to MRI, CTA, or DSA
. Cardiac conditions associated with a high risk of cerebral embolism, including prosthetic heart valves, infective endocarditis, intracardiac thrombus, sick sinus syndrome, cardiac myxoma, or cardiomyopathy with left ventricular ejection fraction \<25% (atrial fibrillation, patent foramen ovale, and atrial septal aneurysm are not exclusion criteria).